News

Multiple sclerosis is dependably among the most expensive chronic diseases to treat, but there are ways to reduce the size of the bill.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses his appreciation for telehealth and remote care, but feels over the next year or so we're going to be seeing more studies come out questioning if some telehealth is needed in certain areas. The discussion came from findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research.

A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.

Amy Abernethy, M.D., Ph.D., hematologist/oncologist and palliative medicine physician and former principal deputy commissioner of the FDA, discusses how the agency handled COVID-19 and what lessons learned will help going forward. Abernethy also addresses if she feels there are enough safeguards of the FDA's independence in place, and reflects on the open FDA commissioner position.

Panelists at 2021 ISPOR say price shouldn't be barrier. Suggestions include steep payment discounts if therapies don't meet outcome goals and regulators removing withdrawing approvals if the therapy doesn't work.

PBMs say exclusions are important for negotiating lower prices on behalf of health plans and members. Some payer and provider groups say they interfere with patient access to medicines.

In this final part of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive spoke with Dr. Sheldon Fields Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, about the ongoing All of Us research program. All of Us is an initiative through partners of the National Black Nurses Association, which Fields is vice president of, and the National Institutes of Health that invites one million people across the U.S. to help build one of the most diverse health databases in U.S. history.

In this first of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive spoke with Dr. Sheldon Fields Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, about the ongoing All of Us research program. All of Us is an initiative through partners of the National Black Nurses Association, which Fields is vice president of, and the National Institutes of Health that invites one million people across the U.S. to help build one of the most diverse health databases in U.S. history.

OptumRx had identified pegcetacoplan as one of the top 5 drugs in the pipeline this year.

Companies are forming and investment dollars are pouring in. Can these services make mental healthcare more accessible and affordable as the pandemic leaves depression and anxiety in its wake?

Sanofi and GlaxoSmithKline’s joint COVID-19 vaccine candidate achieved 95% to 100% seroconversion in a Phase 2 study.

It shouldn’t be just about QALYs and cost. An ISPOR panel today discussed how best to incorporate the patient perspective into value assessment.

Dr. Vivian Lee of Verily Life Sciences addresses if value-based care programs have steered U.S healthcare away from the problems of fee-for-service at a virtual ISPOR meeting today. Lee also shares her thoughts on if the pandemic changed her views of American healthcare.

"COVID. KNOW MORE," is an innovative, timely new initiative empowering Black Americans with the latest information, resources, and updates on COVID-19.

The model has put the patient at the center of healthcare.

Federally Qualified Health Centers have been the safety net for individuals in need for decades. However, even with increasing demand for their services – tripling the number of patients served to more than 28 million since 2000 – FQHCs are not immune from challenges stemming from the pandemic.

Too many study volunteers randomized to the 325-mg dose switched to the 81-mg one to settle the dosage issue But ADAPTABLE is still being celebrated as the kind of "pragmatic study'' that can be a less expensive, more realistic version of the RCT.

The pandemic revealed the fragility, vulnerabilities and unique dangers of working in the healthcare setting. Chief among these was the eroded ability to service patients when there were staff availability issues.

A 13% decline in the past year continues downward. Some of the decline might be explained by pandemic-related drop in healthcare utilization.

Breaches in online vaccination schedulers are the among the security problems the healthcare sector is scrambling to fix.

Every organization should take steps to improve encryption, keep backups up to date, and continually remind employees of the ever present danger of hackers getting into computer systems.

Providers are moving toward acceptance; the rules are here to stay. Payers recognize that people need to know prices.

Smaller providers that have seen sharp declines in revenue may be acquisition targets for large healthcare systems.

Longer half-lives mean less frequent administration and improved quality of life.

The drugs in development include Biogen’s controversial treatment for Alzheimer’s disease and three new drugs for atopic dermatitis.

The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.

Teva is making the first generic version of Absorica (isotretinoin), a drug for the treatment of severe acne.

Young adults did not have significantly better sleep when using blue light filters on their smartphones in the hour before bed, according to a new study.

There’s no going back to the ways of working before COVID-19’s arrival, say many in the industry. Insurers and PBMs are reducing their footprint as work becomes part remote, part in person.